Posters

      Pharmacokinetics of nicotine following single use of a candidate modified risk tobacco product: The Tobacco Heating System 2.1

      Haziza, C.; Baker, G.; Lama, N.; Ancerewicz, J. Ancerewicz.; Picavet, P.; Stewart, A. J.; Lüdicke, F.

      Conference date
      Feb 5, 2014
      Conference name

      Society for Research on Nicotine and Tobacco (SRNT) 2014
      Link to more information
      Topic
      Summary

      To those smokers who are not able or not willing to quit, Philip Morris International (PMI) is investigating alternative approaches by developing products with the potential to reduce the risks of tobacco-related diseases. These products are now referred to by the US Food and Drug Administration as modified risk tobacco products (MRTPs). The challenge in developing and commercializing MRTPs is two-fold, (i.e., developing tobacco products that are shown to reduce risk and that are acceptable to smokers as substitutes for conventional cigarettes (CC). The Tobacco Heating System (THS) 2.1, the MRTP tested in this study is based on the concept  that tobacco is heated at significantly lower temperatures than required for CC. The international  Organization on Standardization  (ISO) yield per THS Tobacco Sticks were: 7 mg for tar, 0.3 mg for nicotine, and  1 mg for carbon monoxide. There are a variety of nicotine-containing products on the market ranging from cigarettes, oral snuff, chewing tobacco to nicotine replacement therapy products (NRT) (gum, inhaler, nasal spray, etc.). There is a large variability of nicotine absorption across this range of products (Molyneux, 2004). For conventional cigarettes, the nicotine is distilled from burning tobacco and carried on liquid droplets which are inhaled and absorbed rapidly across pulmonary membranes. Blood concentrations of nicotine rise very quickly during a smoking session and peak at the completion of smoking (Henningfield, 1995).  It is important to compare nicotine pharmacokinetics for THS 2.1 against CC.

      Related Publications

      Systematic review of the relation between smokeless tobacco and cancer of the pancreas in Europe and North America

      Clinical

      Reduced exposure to Harmful and Potentially Harmful Constituents after 90 days of use of Tobacco Heating System 2.2 Menthol in Japan: A comparison with continued cigarette use or smoking abstinence

      Clinical

      Reduced Exposure To Harmful And Potentially Harmful Constituents after 90 Days Of Use Of Tobacco Heating System 2.2 Menthol In Japan: A Comparison With Continued Cigarette Use Or Smoking Abstinence

      Clinical

      Psychometric Evaluation of the mCEQ applied to Cigarettes and Heat-Not-Burn Products in the US and Japan

      Clinical

      Pharmacokinetics Of Nicotine And Subjective Effects Following The Single Use Of A Non-Menthol And Menthol Version Of Tobacco Heating System 2.2 In Two Studies In Japan: A Comparison With Single Use Of A Combustible Cigarette And Nicotine Gum

      Clinical

      Pharmacokinetics of Nicotine and Subjective Effects Following the Single Use of a Non-Menthol and Menthol Version of Tobacco Heating System 2.2 in Two Studies in Japan: A Comparison with Single Use of a Combustible Cigarette and Nicotine Gum

      Clinical

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.